Fu­ji­film's CD­MO carves foothold in Boston biotech hub with new HQ fo­cused on vi­ral vec­tors, gene ther­a­pies

On the heels of a red-let­ter year for con­tract man­u­fac­tur­ers, Japan’s Fu­ji­film has seen its CD­MO arm — Fu­ji­film Diosynth Biotech­nolo­gies — earn in­ter­est from ma­jor Covid-19 vac­cine mak­ers for its vi­ral-vec­tor ca­pa­bil­i­ties. Now, the drug­mak­er is look­ing to lock down its US foot­print in the bustling Boston biotech hub.

Fu­ji­film will in­vest rough­ly $40 mil­lion (or 4 bil­lion yen) in a new head­quar­ters in the greater Boston area for its CD­MO arm, which will al­so func­tion as its third vi­ral-vec­tor man­u­fac­tur­ing site.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.